According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
rAAV production technology is a key innovation area in cell & gene therapy
rAAV production technology refers to the development and optimization of methods for efficient production and modification of recombinant adeno-associated viruses (rAAVs) for gene therapy applications. This includes, but is not limited to, optimizing vector design, selecting appropriate host cells and vectors, and developing efficient purification methods for scalable production.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 190+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of rAAV production technology.
Key players in rAAV production technology – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to rAAV production technology
Source: GlobalData Patent Analytics
Sanofi is one of the leading patent filers in rAAV production technology. Sanofi is a major pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, and multiple sclerosis, human vaccines for protection against various bacterial and viral diseases, and other indications. The company also offers consumer healthcare products for digestion, allergy, respiratory conditions, pain, women’s health, as well as vitamins, minerals, and supplements. Sanofi’s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. C. H. Boehringer Sohn and Voyager Therapeutics are some of the other key patent filers in rAAV production technology.
In terms of application diversity, Zoetis leads the pack, while German Cancer Research Center and Merck & Co stood in the second and third positions, respectively. By means of geographic reach, 4D Molecular Therapeutics held the top position, followed by Zoetis and Sanofi.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.